Detalhe da pesquisa
1.
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Gynecol Oncol
; 164(1): 12-17, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34763937
2.
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
J Immunother Cancer
; 8(1)2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32503949